All News

Article

Indications Awaiting (12.17.21)

Jack Cush, MD

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory approvals, plus 3 new cases from rheumatologists.

Article

Certain Cancers Increased with Autoimmune Diseases

Jack Cush, MD

Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased risk of cancer, especially in organ-specific immune-mediated diseases. 

Dr. John Cush Tweet
RheumNow
ICYMI: Increased risk death in 310 scleroderma pts: 63 diffuse SSc, 279 limited dz & 33 sine scleroderma (SMR = 1.88). Reduced survival at 10 yrs (78%) & 15 yrs(61%). 69 deaths, 46% in diffuse PSS - due to ILD, PHA, and GI involvement https://t.co/OZg8QamhEB
Dr. John Cush Tweet
RheumNow
Telemedicine? Surveys (patients=1340, MD=111) & interviews (pts= 31, MD= 29) April 2021 and July 2021. Results suggest pts and MDs prefer F2F over Telemedicine almost all categories. Some negatives may be due to the pandemic https://t.co/TdOORCfx6l
Dr. John Cush Tweet
RheumNow
CV mortality with infection & inflammation studied using CDC database; From 1999 to 2018 CV mortality decreased in general population (40.9 to 30.6%) but increased w/ HCV (7.0 -10.2%) & HIV (1.9 to 6.7%); decreased in plateaud in IBD, PSO, RA, and SLE https://t.co/Oiv92xRs6W
Dr. John Cush Tweet
RheumNow
RESTORE trial: yet another failure for PRP injections for knee #OA. Study of 288 Knee oA over 50 years - knee pain scores of −2.1 vs −1.8 on an 11-point scale (range, 0-10) and no difference between PRP and PBO at 12 moshttps://bit.ly/3dZ5ebW
Dr. John Cush Tweet
RheumNow
SOBI has received a positive opinion by the EMA's CHMP on Kineret (anakinra) for the treatment of COVID-19 in adult patients with pneumonia requiring supplemental oxygen or at risk for progressing to severe respiratory failure. Final approval pending https://t.co/1bJYae38hw
Donna Hoyne Tweet
donna_hoyne
It has been a absolute honor to serve the rheum community. Your generous friendship and the ideas sparked on this account inspired me. It was a difficult decision, but yesterday was my last official day at @ACRheum. Thank you for 20+ years of pure goodness. https://t.co/sjAQcgQcSh
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×